Cargando…
2-Oxoesters: A Novel Class of Potent and Selective Inhibitors of Cytosolic Group IVA Phospholipase A(2)
Cytosolic phospholipase A(2) (GIVA cPLA(2)) is the only PLA(2) that exhibits a marked preference for hydrolysis of arachidonic acid containing phospholipid substrates releasing free arachidonic acid and lysophospholipids and giving rise to the generation of diverse lipid mediators involved in inflam...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5539244/ https://www.ncbi.nlm.nih.gov/pubmed/28765606 http://dx.doi.org/10.1038/s41598-017-07330-5 |
Sumario: | Cytosolic phospholipase A(2) (GIVA cPLA(2)) is the only PLA(2) that exhibits a marked preference for hydrolysis of arachidonic acid containing phospholipid substrates releasing free arachidonic acid and lysophospholipids and giving rise to the generation of diverse lipid mediators involved in inflammatory conditions. Thus, the development of potent and selective GIVA cPLA(2) inhibitors is of great importance. We have developed a novel class of such inhibitors based on the 2-oxoester functionality. This functionality in combination with a long aliphatic chain or a chain carrying an appropriate aromatic system, such as the biphenyl system, and a free carboxyl group leads to highly potent and selective GIVA cPLA(2) inhibitors (X (I)(50) values 0.00007–0.00008) and docking studies aid in understanding this selectivity. A methyl 2-oxoester, with a short chain carrying a naphthalene ring, was found to preferentially inhibit the other major intracellular PLA(2), the calcium-independent PLA(2). In RAW264.7 macrophages, treatment with the most potent 2-oxoester GIVA cPLA(2) inhibitor resulted in over 50% decrease in KLA-elicited prostaglandin D(2) production. The novel, highly potent and selective GIVA cPLA(2) inhibitors provide excellent tools for the study of the role of the enzyme and could contribute to the development of novel therapeutic agents for the treatment of inflammatory diseases. |
---|